Revance price target raised to $40 from $29 at Piper Sandler

Piper Sandler analyst David Amsellem raised the firm’s price target on Revance Therapeutics to $40 from $29 and keeps an Overweight rating on the shares after conducting a survey of 26 dermatologists and cosmetic surgeons who are frequent users of aesthetic facial injectables, particularly dermal fillers. The feedback surrounding Revance’s dermal filler franchise was encouraging and suggestive of a continued growing footprint for the product line, the analyst tells investors in a research note. Piper continues to believe Daxxify is well positioned for significant commercial success.